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background: Patients (pt) with chronic kidney disease (CKD) stage V are at high risk for major adverse cardiovascular events (MACE). We sought to 
determine the impact of diabetes (DM) and the presence of overt cardiovascular disease (CVD) on the long-term occurrence of MACE in pt with CKD 
stage V.
methods: 1,516 pt with CKD stage V (61% men, 54±10 years, 40% with DM, and 39% with CVD) were prospectively enrolled; 81 pt were lost to 
follow-up. Pt were divided in groups according to the presence of DM and/or CVD as follows: Group A (n = 632), DM (-)/CVD (-); Group B (n = 243), 
DM (+), CVD (-); Group C (n = 238), DM (-), CVD (+); Group D (n = 322), DM (+), CVD (+). Kaplan-Meier curves for the probability of survival free of 
events (fatal/non-fatal myocardial infarction, unstable angina, stroke, peripheral artery disease, heart failure) was determined for each group during 
a mean follow-up of 29 months (range 1 to 138).
results: There were 332 (23.1%) events. Pt in Group A had the lowest incidence of events (14.1%) whereas pt in Group B had the highest (36.0%; 
P < 0.001). The figure shows that the was no difference in the incidence of events between pt in Groups B (24.3%) and C (28.6%) (P=ns).
conclusions: In pt with CKD stage V, DM is an equivalent to CVD as a long-term predictor of MACE. This data should prompt for an aggressive 
management of pt with DM and CKD, even without CVD, in order to improve their long-term prognosis.
 
